A detailed history of Loomis Sayles & CO L P transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Loomis Sayles & CO L P holds 837 shares of GILD stock, worth $69,981. This represents 0.0% of its overall portfolio holdings.

Number of Shares
837
Previous 3,568 76.54%
Holding current value
$69,981
Previous $261,000 78.16%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$63.15 - $72.88 $172,462 - $199,035
-2,731 Reduced 76.54%
837 $57,000
Q1 2024

May 14, 2024

SELL
$71.58 - $87.29 $5,583 - $6,808
-78 Reduced 2.14%
3,568 $261,000
Q4 2023

Feb 13, 2024

SELL
$73.27 - $83.09 $14,287 - $16,202
-195 Reduced 5.08%
3,646 $295,000
Q3 2023

Nov 09, 2023

BUY
$73.94 - $80.67 $220,932 - $241,041
2,988 Added 350.29%
3,841 $288,000
Q2 2023

Aug 11, 2023

BUY
$76.01 - $86.7 $3,952 - $4,508
52 Added 6.49%
853 $66,000
Q1 2023

May 11, 2023

SELL
$77.31 - $88.08 $40,587 - $46,242
-525 Reduced 39.59%
801 $66,000
Q4 2022

Feb 10, 2023

BUY
$62.32 - $89.47 $50,666 - $72,739
813 Added 158.48%
1,326 $114,000
Q3 2022

Nov 14, 2022

SELL
$59.54 - $68.01 $221,250 - $252,725
-3,716 Reduced 87.87%
513 $32,000
Q2 2022

Aug 05, 2022

SELL
$57.72 - $65.01 $4,617 - $5,200
-80 Reduced 1.86%
4,229 $261,000
Q1 2022

May 13, 2022

SELL
$57.92 - $72.58 $29,539 - $37,015
-510 Reduced 10.58%
4,309 $256,000
Q4 2021

Feb 14, 2022

SELL
$64.88 - $73.64 $20,437 - $23,196
-315 Reduced 6.14%
4,819 $350,000
Q3 2021

Nov 12, 2021

SELL
$67.69 - $73.03 $49,278 - $53,165
-728 Reduced 12.42%
5,134 $359,000
Q2 2021

Aug 13, 2021

SELL
$63.47 - $69.35 $1.57 Million - $1.72 Million
-24,762 Reduced 80.86%
5,862 $404,000
Q1 2021

May 17, 2021

BUY
$60.0 - $68.46 $1.81 Million - $2.07 Million
30,230 Added 7672.59%
30,624 $1.98 Million
Q4 2020

Feb 12, 2021

SELL
$56.65 - $64.55 $884,136 - $1.01 Million
-15,607 Reduced 97.54%
394 $23,000
Q3 2020

Nov 12, 2020

BUY
$62.1 - $78.08 $829,159 - $1.04 Million
13,352 Added 504.04%
16,001 $1.01 Million
Q2 2020

Aug 14, 2020

BUY
$72.34 - $84.0 $138,024 - $160,272
1,908 Added 257.49%
2,649 $204,000
Q1 2020

May 15, 2020

SELL
$62.63 - $80.22 $1.85 Million - $2.37 Million
-29,525 Reduced 97.55%
741 $55,000
Q4 2019

Feb 14, 2020

SELL
$61.62 - $67.78 $1.78 Million - $1.96 Million
-28,868 Reduced 48.82%
30,266 $1.97 Million
Q3 2019

Nov 13, 2019

SELL
$62.51 - $69.0 $588,031 - $649,083
-9,407 Reduced 13.72%
59,134 $3.75 Million
Q2 2019

Aug 14, 2019

BUY
$61.87 - $69.38 $1.41 Million - $1.58 Million
22,721 Added 49.59%
68,541 $4.63 Million
Q1 2019

May 15, 2019

BUY
$62.53 - $70.05 $594,785 - $666,315
9,512 Added 26.2%
45,820 $2.98 Million
Q4 2018

Feb 14, 2019

BUY
$60.54 - $79.0 $2.16 Million - $2.81 Million
35,623 Added 5200.44%
36,308 $2.27 Million
Q3 2018

Nov 13, 2018

SELL
$71.28 - $78.92 $333,305 - $369,029
-4,676 Reduced 87.22%
685 $53,000
Q2 2018

Aug 14, 2018

BUY
$64.88 - $75.68 $347,821 - $405,720
5,361 New
5,361 $380,000
Q1 2018

May 11, 2018

SELL
$72.84 - $88.8 $11,727 - $14,296
-161 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$71.15 - $83.52 $257,064 - $301,757
-3,613 Reduced 95.73%
161 $12,000
Q3 2017

Nov 14, 2017

BUY
$72.11 - $85.47 $272,143 - $322,563
3,774
3,774 $306,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $105B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Loomis Sayles & CO L P Portfolio

Follow Loomis Sayles & CO L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.